Home > GAMMAGARD Products > GAMMAGARD LIQUID SC

GAMMAGARD LIQUID SC

Subcutaneous (SC) administration may be the right choice for your patients.

Protect life's moments with:


aThe safety of GAMMAGARD LIQUID in SC infusions was evaluated in 47 subjects.


Selected Important Risk Information

  • The most common adverse reactions observed in ≥ 5% of patients in the clinical trials for PI (SC administration) were: Infusion site (local) event, headache, fatigue, heart rate increased, pyrexia, abdominal pain upper, nausea, vomiting, asthma, blood pressure systolic increased, diarrhea, ear pain, aphthous stomatitis, migraine, oropharyngeal pain, and pain in extremity.

References: 1. GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% [Prescribing Information]. Westlake Village, CA: Baxter Healthcare Corporation. April 2014. 2. Wasserman RL, Melamed I, Kobrynski L, et al. Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. J Clin Immunol. 2011;31:323-331.


  • Your patients can get access to experienced Patient and Nurse Advocates, insurance and financial support, useful tools, and more.
    Find Out How
  • Clinical Study Video Learn more about the clinical study of the subcutaneous administration of GAMMAGARD LIQUID.
    View study presentation

You are now leaving GAMMAGARD.com

Shire is not responsible for the privacy policy, the content or the accuracy of any web site accessed through a link on the GAMMAGARD.com site. A link to other web sites does not constitute an endorsement of Shire of the linked site, its products or services.

The browser window or tab for GAMMAGARD.com will remain open underneath the new browser window or tab. To return to GAMMAGARD.com at any time, close this tab or window.

Return to
GAMMAGARD.com
Continue